Clinical trials
Metastatic Liver Cancer clinical trials
Below are recruiting metastatic liver cancer clinical trials, each written for real people, not researchers. We’re tracking 817 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06369831RecruitingPhase 2
Imaging test for HER2 in metastatic cancer
This trial uses a special imaging scan to see if your cancer has HER2 on its surface, which could help decide if HER2-targeted treatment might work for you. It's for people with metastatic breast cancer or other solid tumors that have spread.
Innsbruck, TyrolAges 18 years+ - NCT06099769RecruitingPhase 2
Testing enzalutamide with or without mifepristone for AR-positive breast cancer
This trial tests if adding the drug mifepristone to the standard antiandrogen enzalutamide works better than enzalutamide alone or chemotherapy for people with a specific type of breast cancer that has androgen receptors. It aims to find a new targeted treatment option for triple-negative or ER-low breast cancer.
Birmingham, AlabamaAges 18 years+ - NCT05611034RecruitingPhase 1
Testing a lung treatment for colorectal cancer spread to lungs
This Phase 1 trial tests a targeted treatment delivered to the lungs for colorectal cancer that has spread to the lungs. It aims to see if the approach is safe and can reach lung tumors, especially when there are multiple lung lesions.
Toronto, OntarioAges 18–70 - NCT05286814RecruitingPhase 2
Pump-delivered therapy plus chemo for liver-metastatic cancers
This phase 2 study tests a liver-targeted medicine delivered through a special implanted pump, combined with standard chemo, for cancers that spread mainly to the liver. It may help control tumor growth in the liver and improve outcomes compared with standard treatment alone.
Bethesda, MarylandAges 18–120 - NCT02174549RecruitingPhase 1/Phase 2
Testing a drug with liver artery treatment for liver-spread neuroendocrine cancer
This early-stage study tests a cancer drug called tirapazamine, given along with a liver artery procedure (embolization) to treat liver-dominant metastatic neuroendocrine tumors. It aims to find a safe dose and see whether the combination can better control tumor growth in the liver.
Palo Alto, CaliforniaAges 20–99 - NCT00068003Enrolling by invitation
Harvesting Cancer Cells for Experimental Treatment
This trial collects immune cells from cancer patients or healthy volunteers to develop new experimental cancer treatments. Researchers will take a sample of your tumor or blood cells, grow them in the lab, and study how to use them to fight your cancer.
Bethesda, MarylandAges 18 years+ - NCT06936527Enrolling by invitationPhase 1/Phase 2
XS-03 plus chemotherapy and bevacizumab for metastatic colorectal cancer with RAS mutation
This trial tests an experimental drug called XS-03 combined with standard chemotherapy (FOLFOX or FOLFIRI) plus a targeted therapy (bevacizumab) for people with metastatic colorectal cancer that has a RAS mutation. The goal is to see if adding XS-03 helps shrink tumors or slows cancer growth better than current treatments.
BeijingAges 18–75 - NCT06583070Recruiting
SABR plus targeted therapy and immunotherapy for advanced kidney cancer
This trial tests combining a precise type of radiation (SABR) with standard targeted therapy and immunotherapy drugs for kidney cancer that has come back or spread. The goal is to see if adding radiation improves outcomes.
Beijing, Beijing MunicipalityAges 18–85 - NCT05570994Enrolling by invitationPhase 1/Phase 2
PSMA-targeted radioactive drug for advanced prostate cancer
This Phase 1/2 study tests a radioactive treatment that targets PSMA, a protein often found on prostate cancer cells. It’s for men whose prostate cancer has worsened despite hormone-blocking pills like abiraterone or enzalutamide, aiming to help shrink or control the disease.
Vancouver, British ColumbiaAges 18 years+ - NCT04263298RecruitingPhase 3
Fulvestrant or capecitabine after chemo for metastatic breast cancer
This Phase 3 trial compares two medicines—fulvestrant versus capecitabine—as “maintenance” treatment after your first chemo helps control metastatic breast cancer. It aims to see which one helps people live longer with better disease control.
Guangzhou, GuangdongAges 18–75 - NCT06118762RecruitingPhase 4
Study of fruquintinib plus raltitrexed for advanced colorectal cancer
This trial tests two drugs, fruquintinib and raltitrexed, for people with metastatic colorectal cancer that has stopped responding to or is no longer tolerable after standard treatments like fluorouracil, oxaliplatin, and irinotecan. The goal is to see if this combination can help shrink or control the cancer.
Nanchang, JiangxiAges 18 years+ - NCT06242067RecruitingPhase 2
Second-line treatment for advanced colorectal cancer
This trial tests a new treatment for people with advanced colorectal cancer that has spread or come back after initial chemotherapy. It is for those who have already received standard first-line therapy and are now looking for a second treatment option.
Jinan, ShandongAges 18–75 - NCT05007132RecruitingPhase 2
First-line metastatic colon or rectal cancer study with targeted drugs
This Phase 2 trial compares two treatment combinations as a first treatment for metastatic (spread) colon or rectal cancer. It looks to see whether one combo works better or is safer than the other.
BerlinAges 18 years+ - NCT06243393RecruitingPhase 2/Phase 3
Sacituzumab govitecan for advanced colorectal cancer
This study tests a drug called sacituzumab govitecan for people with metastatic colorectal cancer who have already tried several standard treatments. It may be an option if your cancer is not MSI-H or dMMR and you haven't had irinotecan recently.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT07790510RecruitingPhase 1/Phase 2
Study of HSK42360 with cetuximab for BRAF-mutated colorectal cancer
This trial tests an experimental drug (HSK42360-Na) combined with standard treatments (cetuximab with or without chemotherapy) for people with advanced colorectal cancer that has a specific BRAF mutation. The goal is to see if this combination can shrink tumors or slow their growth, and to check its safety.
BeijingAges 18 years+ - NCT06341296RecruitingPhase 2
Irinotecan liposomes for first-line advanced colorectal cancer
This trial tests a new type of chemotherapy (irinotecan liposomes) as a first treatment for metastatic colorectal cancer that has not been treated before. It focuses on patients with specific genetic changes (RAS or BRAF V600E mutation) or right-sided colon cancer, and looks at how well the drug works.
Sichuan, Sichuan, ChengduAges 18–85 - NCT06563986RecruitingPhase 2
Combination therapy for advanced colorectal cancer in the liver
This trial tests a combination of two chemotherapy drugs (FTD and tipiracil), a targeted therapy (bevacizumab), and a radiation treatment (radioembolization) for people with colorectal cancer that has spread mainly to the liver and hasn't responded to other treatments. The goal is to see if this combination can shrink tumors and help control the cancer.
UtrechtAges 18 years+ - NCT06641544RecruitingPhase 4
Testing different drug combos for HER2-positive breast cancer
This trial tests different combinations of the drug Inetetamab as a first treatment for breast cancer that has spread and is HER2-positive. It aims to find which combo works best and is safe for newly diagnosed metastatic patients.
Shanwei, GuangdongAges 18–70 - NCT06685276RecruitingPhase 2
Combination therapy for advanced colorectal cancer
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
BeijingAges 18–75 - NCT07559760RecruitingPhase 2
New combination therapy for advanced colorectal cancer after first treatment
This trial tests a new drug combination for colorectal cancer that has spread to other parts of the body and did not respond to or could not tolerate standard first-line chemotherapy. The goal is to see if this new approach can help shrink the cancer and extend survival.
Changchun, JilinAges 18–75 - NCT05462613RecruitingPhase 2/Phase 3
Regorafenib plus aspirin then standard chemo for metastatic bowel cancer
This trial tests whether adding regorafenib and low-dose aspirin before standard chemotherapy can slow metastatic colorectal cancer after it has progressed on prior treatment. It may help by trying a different cancer-fighting approach earlier, followed by the usual chemo plan.
BesançonAges 18 years+ - NCT06425133RecruitingPhase 2
Regorafenib plus low-dose chemo for advanced colorectal cancer
This trial tests a combination of regorafenib (a targeted pill that cuts off blood supply to tumors) with a low-dose, continuous chemotherapy regimen for people whose colorectal cancer has spread and is no longer responding to standard treatments. The goal is to see if this mix can slow or stop the cancer's growth.
AuxerreAges 18 years+ - NCT07524855RecruitingPhase 1
Study of a new drug for metastatic breast cancer
This trial tests an experimental drug called JNJ-101684362 (HLD-0117) for people with metastatic breast cancer that has not responded to other treatments. It may help by targeting cancer cells in a new way, and the study will check if it is safe and effective.
New Haven, ConnecticutAges 18 years+ - NCT06282445RecruitingPhase 2
Combination therapy for first-line metastatic colorectal cancer
This trial tests whether adding the immunotherapy drug adebrelimab to standard chemotherapy plus bevacizumab can help people with a specific type of metastatic colorectal cancer that cannot be removed by surgery. It is for patients whose tumors are microsatellite stable (MSS) or have normal mismatch repair (pMMR).
Jinhua, ZhejiangAges 18–75
Hear when a new Metastatic Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic liver cancer?
- Yes. Clin2 currently lists 817 recruiting metastatic liver cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic liver cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic liver cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.